Leading Global Players Back and Fund Pluri’s Cell-Based Food and Agriculture Collaborations

Rhea-AI Summary

Pluri (NASDAQ, TASE: PLUR) announced on November 10, 2025 a series of international strategic collaborations across Asia, Europe and the U.S. through its subsidiaries Ever After Foods, Kokomodo and Coffeesai to advance cultivated meat, cultivated cacao and cell-based coffee.

Each collaboration is anchored by a collaborator-funded minimum-viable-product (MVP) / proof-of-concept to support scale-up validation, pre-commercial trials and pilot results, with near-term milestones focused on pilot readouts and expansion of collaborator programs in priority markets.

Positive

• Signed collaboration agreements across Asia, Europe and the U.S. (Nov 10, 2025)
• Each agreement includes a collaborator-funded MVP/POC
• Near-term milestones: pilot results and expansion of collaborator programs

Negative

• None.

Insights

Foodtech Strategic Analyst

Strategic, collaborator‑funded MVPs across Asia, Europe and the U.S. signal near‑term commercialization steps for Pluri's foodtech subsidiaries.

Pluri's model pairs its 3D cell‑expansion platform with collaborator‑funded minimum‑viable‑product workstreams, which shifts early technical and financial risk to partners while generating pilot data and potential commercial pathways. The three subsidiaries — Ever After Foods, Kokomodo, and Coffeesai — target cultivated meat, cultivated cacao, and cell‑based coffee respectively, with programs described as scale‑up validation, pre‑commercial trials, and co‑development agreements across Asia, Europe and the U.S. These activities convert development pipeline items into pilot results and partner commitments that can be monitored.

The principal dependencies and risks are explicit: outcomes hinge on the collaborator‑funded proofs‑of‑concept and pilot results, which determine technical de‑risking and market fit. The release states funding and MVP structures but gives no financial figures, timelines, or success criteria; that leaves uncertainty about commercial scale, margin profile, and rollout cadence. Monitorable items include pilot results and expansion of collaborator programs in priority markets, and the announcement date November 10, 2025 provides a reference point for expected near‑term milestones.

• Pluri entered strategic collaborations across Asia, Europe and the United States (“U.S.”) to transform food and agriculture production via its subsidiaries’ advanced cell expansion technologies 
• Pluri’s subsidiaries Ever After Foods, Kokomodo, and Coffeesai will potentially expand market presence in cultivated meat, cultivated cacao, and cell-based coffee industries amid growing global demand for scalable, sustainable solutions
• Each collaboration is anchored by a minimum-viable-product (“MVP”), funded by leading global players entering an agreement. This structure is aimed at bringing the parties’ substantial commitment and trust in the collaboration’s innovative potential
  

HAIFA, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, has entered into a series of significant international collaborations across its foodtech and agtech subsidiaries. These collaborations represent a major step forward in Pluri’s mission to transform food and agriculture production through its advanced 3D cell-expansion technology and scalable innovations.

Pluri’s three subsidiaries, Ever After Foods Ltd. (“Ever After Foods”), Kokomodo Ltd. (“Kokomodo”), and Coffeesai Ltd. (“Coffeesai”), have signed collaboration agreements with key global food and agtech leaders in Asia, Europe, and the U.S. We believe this expansion reflects both increasing commercial viability and rising global demand for sustainable, cell-based innovations.

• Ever After Foods, developer of a proprietary cultivated-meat platform, is executing several programs across Asia and the U.S. with food companies and cultivated-meat players. These programs are advancing scale-up validation and pre-commercial trials on collaborator use cases, turning pipeline into pilot results and de-risking technical pathways. With a capital-efficient business-to-business model, Ever After Foods is positioned to scale alongside collaborators while maintaining disciplined spend. Near-term milestones include pilot results and expansion of collaborator programs in priority markets, potentially opening several go-to-market options and supporting long-term sustainability and food security.
• Kokomodo, which produces real, controlled, climate-resilient cacao using cellular agriculture technology, has signed two new strategic agreements: one agreement with a European food innovation firm that specializes in the production of confectionery, and another agreement with a U.S.-based multinational company that provides food, agriculture, financial and industrial products and services. These collaborations aim to enable Kokomodo to expand its research, development, and manufacturing capabilities while exploring co-development opportunities across Europe and North America.
• Coffeesai, which advances eco-friendly and resource-efficient coffee production through cell-based cultivation in controlled indoor environments, has entered a strategic collaboration with a major food and beverage conglomerate headquartered in East Asia. The partnership will accelerate Coffeesai’s mission to deliver eco-friendly, resource-efficient cellular coffee production through cell cultivation, minimizing the environmental toll of traditional farming while simplifying complex logistics by bringing production closer to consumers.
  

“These collaborations represent a major leap forward in our foodtech and agtech roadmap,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “We believe that each collaboration not only validates the market readiness and multifaceted potential of our scalable 3D cell expansion technologies but also brings the power of world-class collaborators into our ecosystem. Together, we aim to reshape the way the world produces and consumes essential food products. We believe that the fact that every agreement includes a collaborator-funded proof-of-concept (“POC”) is a clear vote of confidence in our technology and reinforces our ability to deliver sustainable, long-term value for our shareholders.”

Pluri’s momentum comes at a critical moment, with demand for sustainable solutions for traditional agriculture on the rise amid challenges such as warming climates, dwindling natural resources, and an increasing global population. By leveraging its proprietary 3D cell expansion platform, Pluri’s technology enables rapid scaling of next-generation food and agriculture solutions with significantly reduced environmental footprints.

About Pluri Inc.
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, and offers Contract Development and Manufacturing Organization services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.

Forward-Looking Statements

This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses Pluri’s subsidiaries’ expansion of market presence; the expansion of strategic collaborations reflecting both increasing commercial viability and rising global demand for sustainable, cell-based innovations; Ever After Foods’ ability to advance scale-up validation and pre-commercial trials on collaborator use cases, turn pipeline into pilot results and de-risk technical pathways; Ever After Foods’ position to scale while maintaining disciplined spend; Ever After Food’s ability to meet milestones such as pilot results and expansion of collaborator programs in priority markets, including opening go-to-market options and supporting long-term sustainability and food security; Kokomodo’s collaborations’ goal to enable it to expand its research, development, and manufacturing capabilities while exploring co-development opportunities across Europe and North America; the ability to accelerate Coffeesai’s mission to deliver eco-friendly, resource-efficient cellular coffee production through cell cultivation and minimize the environmental toll of traditional farming while simplifying complex logistics by bringing production closer to consumers; the belief that the collaboration validate the market readiness and multifaceted potential of our scalable 3D cell expansion technologies and brings the power of world-class partners into Pluri’s ecosystem; Pluri’s goal to reshape the way the world produces and consumes essential food products; the belief that the fact that every collaboration includes a partner-funded POC is a vote of confidence in Pluri’s technology and reinforces Pluri’s ability to deliver sustainable, long-term value for its shareholders and by leveraging its proprietary 3D cell expansion platform; and Pluri’s technology ability to enable rapid scaling of next-generation food and agriculture solutions with significantly reduced environmental footprints. These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in consumer preferences or aesthetics industry trends; Pluri or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by Pluri or its partners/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.

Contacts
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Israel Media: Shachar Yental at shacharye@gitam.co.il

FAQ

What did Pluri announce on November 10, 2025 regarding PLUR collaborations?

Pluri announced strategic collaboration agreements across Asia, Europe and the U.S. via subsidiaries Ever After Foods, Kokomodo and Coffeesai.

How are Pluri’s collaborations for PLUR funded and structured?

Each collaboration is anchored by a collaborator-funded MVP/POC to validate scale-up and pre-commercial trials.

What near-term milestones did Pluri disclose for PLUR’s foodtech subsidiaries?

Pluri highlighted pilot results and expansion of collaborator programs in priority markets as near-term milestones.

Which Pluri subsidiaries are involved in the November 10, 2025 collaborations for PLUR?

Ever After Foods (cultivated meat), Kokomodo (cultivated cacao) and Coffeesai (cell-based coffee) are the collaborating subsidiaries.

What markets will PLUR’s new collaborations target?

The collaborations target commercial and development programs across Asia, Europe and North America (U.S.).

What is the intended business model impact of the PLUR collaborations for Ever After Foods?

Ever After Foods expects a capital-efficient B2B approach to scale with collaborators while advancing scale-up validation and pre-commercial trials.